In addition, recent preclinical work identified Tregs as promising immunotherapeutic targets: a 2025 study using CAR-Treg cells directed against VCAM-1 demonstrated attenuation of aneurysm progression, indicating that modulation of Treg number or function may help limit disease development [154]. Here, VCAM1 is linked to aneurysm.